Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
Yahoo Finance

Cofactor Genomics Presents Breakthrough Work Combining RNA and AI to bring Precision Medicine to Immunotherapy at RNA Society’s 30th Annual Meeting

SAN DIEGO, May 30, 2025--(BUSINESS WIRE)--Cofactor Genomics announced the latest validation results for OncoPrism ®, Cofactor’s breakthrough RNA-based diagnostic approach at the RNA Society’s 30th ...
Yahoo Finance

Cofactor Genomics Publishes Analytical Validation of OncoPrism-HNSCC, Highlighting Robustness of The AI-powered RNA Test In Predicting Cancer Patient Response To Immunotherapy

SAINT LOUIS, February 12, 2025--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their analytical ...
Business Wire

Precision Medicine Global Thought Leader, Dr. Howard McLeod, Joins Cofactor Genomics’ Advisory Board as Cofactor Brings OncoPrism test to Partnered Hospitals

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today that Dr. Howard McLeod, Pharm.D., FASCO, FCCP, has ...